Share

November 2021; 8 (6) Views & ReviewsOpen Access

Neurosarcoidosis

Pathophysiology, Diagnosis, and Treatment

Michael J. Bradshaw, Siddharama Pawate, Laura L. Koth, Tracey A. Cho, Jeffrey M. Gelfand
First published October 4, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001084
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
9048

Share

Article Information

vol. 8 no. 6 e1084
DOI: 
https://doi.org/10.1212/NXI.0000000000001084
PubMed: 
34607912
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received March 20, 2021
  • Accepted in final form July 12, 2021
  • First Published October 4, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Michael J. Bradshaw, MD*,
    2. Siddharama Pawate, MD (siddharama.pawate{at}vanderbilt.edu),
    3. Laura L. Koth, MD (laura.koth{at}ucsf.edu),
    4. Tracey A. Cho, MD (tracey-cho{at}uiowa.edu) and
    5. Jeffrey M. Gelfand, MD, MAS, FAAN* (jeffrey.gelfand{at}ucsf.edu)
  1. Michael J. Bradshaw, MD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Continuum: lifelong learning in neurology, editorial board member, 1 year

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Siddharama Pawate, MD (siddharama.pawate{at}vanderbilt.edu),
    3. Scientific Advisory Boards:

    1. Biogen advisory board Alexion advisory boards

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen Genentech

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Laura L. Koth, MD (laura.koth{at}ucsf.edu),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. MEDIMMUNE, COMMERCIAL

    Research Support, Government Entities:

    1. NIH, PI, 2016 AND 2017

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Tracey A. Cho, MD (tracey-cho{at}uiowa.edu) and
    5. Scientific Advisory Boards:

    1. (1) DSMB: A Randomized Trial of Combined Albendazole plus Praziquantel for Subarachnoid Cysticercosis of the Sylvian Fissure or the Basal Cisterns; NIH; 2018: $400

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Speaker honorarium, AAN: $1,000 [2019]

    Editorial Boards:

    1. (1) Up To Date: $123

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Josalyn Cho (wife) NIH/NIAID K08AI113083 Principal Investigator 2014-2019 (2) Josalyn Cho (wife) NIH/NIAID UH2AI44434 PI 2019-2020 (3) Josalyn Cho (wife) NIH/NHLBI R01HL148758 PI 2020-2025

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Jeffrey M. Gelfand, MD, MAS, FAAN* (jeffrey.gelfand{at}ucsf.edu)
    6. Scientific Advisory Boards:

    1. DSMB for a National Institutes of Aging funded study.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Dr. Gelfand is on the editorial advisory board of Neurology: Neuroimmunology & Neuroinflammation. Dr. Gelfand's spouse is Editor-in-Chief of Headache and previously served on the editorial team of JAMA Neurology.

    Patents:

    1. NONE

    Publishing Royalties:

    1. Honoraria from Dynamed Plus for editorial review. Dr. Gelfand's spouse has received honoraria from UpToDate.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consulting for Biogen. His spouse has received prior consulting fees from Biohaven, Advanced Clinical, Theranica, and Satsuma.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support to University of California, San Francisco from Genentech/Roche. His spouse has received grant support from Amgen.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. PI of an Institutional Clinician Training Award from the National MS Society.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Dr. Gelfand has received compensation for medical-legal consulting as an expert witness; his spouse has also received personal compensation for medical- legal consulting as an expert witness.

  1. From the University of Washington and Billings Clinic, (M.J.B.); Vanderbilt University Medical Center (S.P.), Nashville, TN; Division of Pulmonary and Critical Care (L.L.K.), Department of Medicine, University of California, San Francisco; Division of Pulmonary and Critical Care, Department of Medicine; Univeristy of Iowa (T.A.C.), Iowa City; Department of Neurology (J.M.G.), Division of Neuroimmunology and Glial Biology, University of California, San Francisco.
  1. Correspondence
    Dr. Bradshaw bradshaw.michaelj{at}gmail.com, or Dr. Gelfand jeffrey.gelfand{at}ucsf.edu
View Full Text

Article usage

Article usage: October 2021 to August 2023

AbstractFullPdfSource
Oct 20211831621758Highwire
Nov 2021191153651Highwire
Dec 2021171137344Highwire
Jan 2022151219281Highwire
Feb 2022261183283Highwire
Mar 2022351347318Highwire
Apr 202251199262Highwire
May 2022191199223Highwire
Jun 2022221125229Highwire
Jul 2022231372221Highwire
Aug 2022231700248Highwire
Sep 2022241391273Highwire
Oct 2022281712312Highwire
Nov 2022231537245Highwire
Dec 2022261367271Highwire
Jan 2023211612312Highwire
Feb 2023251890408Highwire
Mar 2023502268422Highwire
Apr 2023301966409Highwire
May 2023512616451Highwire
Jun 2023412249366Highwire
Jul 2023391911351Highwire
Aug 2023481763410Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me